Safety Study for Beta Thalassemia Subjects on PTG-300

Clinical trial NCT04054921 · COMPLETED

Trial details

NCT number: NCT04054921
Sponsor: Protagonist Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

β-thalassemia Ineffective Erythropoiesis

Start date: 2019-05-10
Primary completion: 2020-07-31
Enrollment: 34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.